Podcasts about semaglutide

In Part 1 we started discussing the study Two Years After Stopping GLP-1s, Most Patients Sustain at Least Some Weight Loss by Bartelt et al. which I identified as possibly the worst, and definitely among the top 3 worst, studies I've ever analyzed.In part 1 we talked about the platform (Epic Research), the researchers, and the basic methodology for reporting. Today we're going to get into the analysis. Remember that there are two sources, the first is the actual article, the second is what I am calling the supplementary materials that is a pdf that is linked (though not at all clearly) in the article.We'll compare the claims made in the article to the data shown in the supplementary materials. I think as we get into this it may be helpful (and maybe just a bit comforting) to remember that this was not published in a peer reviewed journal - it's Epic publishing Epic's research on Epic's website.We'll begin with the most basic claim: “we studied 188,722 patients who stopped using a GLP-1 medication after being on it for at least 90 days and who lost at least 5 pounds while on it.”You might be thinking “wait - in Part 1 you said the study population was 323,782, what happened to the other 135,060 people? Let's go on this journey together. We'll start by looking at their data. In the supplementary materials, Table 1: Characteristics of the Study Population looks like this:So they say in the article that they studied 188,722 patients but the very first line of the supplementary materials chart about the study population says that the total number of patients was 323,782. But it gets a bit weirder, if you add up all the participants in the different age categories you get 323,750, 32 short. If you add up the totals across the drug groups you do get 188,722, if you add up the participants in the weight loss category you get 323,782. If you add up the diabetic status you get 323,782. What is going on here? Maybe they originally looked at 323,782 records of which only 188,722 were not excluded for some reason, and maybe 32 of the participants did not have an age on their electronic health record? At least the number of people across the drug groups in the supplementary materials chart matches the number of people they claim to have studied but this is, in the absolute more charitable description, an extremely confusing way to present this data.In part 1 we discussed the fact that the inclusion criteria were not particularly stringent but the biggest issue, to me, is that the researchers appear to have just done calculations with whatever data they happened to have, but reported it and drew conclusions as if they had consistent data on all participants.For each of the three drug groups (semaglutide, liraglutide, tirzepatide), they present an interactive graph that shows “the proportion of patients by amount of weight regained or lost after stopping [liraglutide/semaglutide/tirzepatide].”Let's dig in.In the article we find Figure 1 - Proportion of Patients by Weight Change After Stopping Semaglutide we can see in the lower left “n=139,972 patients.”But if you look at the supplementary materials you find Table 2 Proportion of Patients by Weight Change After Stopping Semaglutide. This is the table from which they are drawing the data for Figure 1.The final column of the supplemental table is “patients” and the number in that column represents the number of the original 139,972 patients who had taken (and subsequently stopped taking) semaglutide for which the researchers had a weight at each month of their calculation. At month 1, the researchers had a weight for 68,754 of the patients and this number trends steadily downward until month 24 when they only had weights for 2,650 of the original 139,972 patients. At literally no point does Figure 1 in the original article give data for the n=139,972 patients the label claims.In the liraglutide group the graph in the article says n = 23,377. The supplementary tables show that in month 1 they had weights for 11,580. That steadily declined until month 24 they had weights for 1,268 of the population.In the tirzepatide group, the article says n= 25,373 patients. At month 1 they had weights for 12,909 patients which steadily declined until at at month 24 they only had a weight for 145 people (that is not a typo, they were doing the two year calculation upon which they drew their bold conclusions with only one hundred and forty five of the original 25k+ people represented!)This is such a bonkers way to do this that I actually emailed them, using the semaglutide table as an example, to make sure I was understanding this correctly. They assured me that I was:“Yes – there were 139,972 total patients on semaglutide who met the conditions in the study cohort. The patient count in Table 2 represents the number of patients that had a weight reading in a given month, so patients can be represented in multiple months.”So let's discuss the “key findings”At 24 months post-cessation, 56% of semaglutide, 52% of liraglutide, and 55% of tirzepatide patients kept the weight off or lost additional weight.Complete weight regain occurred in 23% of semaglutide, 21% of tirzepatide, and 27% of liraglutide users at 24 months.Weight trajectories stabilized after 12 months, with only small variations in the distribution of weight outcomes through year two.Remember that when they state these 24 month findings (or when in the title they say “Most Patients Sustain at Least Some Weight Loss,”) these statistics are drawn from information for only 1.9% of the semaglutide group, 5.4% of the liraglutide group, and 0.57% of the tirzepatide group. When they say kept the weight off or lost additional weight, subjects would qualify if they maintained 1% of the weight they lost. EDIT - I'm adding this paragraph for additional clarification based on a great comment below. If you look at their percentages, it can seem like a lot of people didn't regain weight. For example in the Semaglutide group, for example, at 1 month the “doubled their weight loss group” was 5.01% of 68,754 participants. That's that's about 892 people which is 0.64% of the original 139,972 people. At 24 months it was 25.89% of 2,650 people. That's about 686 people which is about 0.49% of the original 139,972 people. As I mentioned in part 1, we also don't know if this miniscule percentage of the total group even actually stopped taking the drugs, or if they started getting them from a different source that did not add them to their medical chart.What happened to the 98.1% of the semaglutide group, 94.6% of the liraglutide group, and the staggering 99.43% of the tirzepatide group for whom the researchers did NOT have a weight at 24 months? Is it more likely that people who were regaining weight did not come back to get weighed in? These researchers have absolutely no idea and they don't seem to care.(They said that weight trajectories stabilized at 12 months so even if we look at the data at 12 months they only had weights for 12.7% of the semaglutide group, 18.5% of the liraglutide group, and 8.1% of the tirzepatide group.)Under limitations they state “We allow a patient to be included in each month, using their highest weight in that month. Patients who have repeated weight measurements might be the extremes of weight change.”Gentle readers, I would say that this is the least of their limitations. The fact that they are stating these incredibly broad conclusions about weight regain (including in the title!) based on a tiny fraction of the data they've led us to believe is included, and that they AT NO POINT disclose any of that in the main paper is, to me, unforgivable. Horrifyingly, in researching this piece I found other studies that actually cited this one so I'll end this by saying that this study completely lacks the academic rigor or appropriate methodology necessary to be used to counter research showing high rates of weight regain after GLP-1 cessation. GLP-1s are being taken by a huge percentage of people and being prescribed (and in some cases pushed) by many prescribers, research like this has the potential to do incredible harm by generating blatant misinformation. We have to do a whole lot better than this.This month's online workshop is How to Be Your Own Medical Advocate. You'll learn strategies to advocate for yourself to help you get the evidence-based, compassionate, healthcare you deserve, and what your options are if you don't. There's a pay-what-you-can option to make sure money isn't a barrier and all registrants get a video in case you can't make it live. Details and registration are here! If you appreciate the work I do here, you can support my ability to do more becoming a free or paid subscriber!Liked the piece? Share the piece!More researchThe Research PostMore resourcesThe Resource Post*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings' Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison's Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

REPLAY! Bariatric surgery is the most effective tool for lasting weight loss, and her experience performing thousands of procedures has given Dr. Betsy Dovec a clear understanding of what can help patients succeed.In this episode of Wellness Junkies, host Amy Sherman sits down with Dr. Dovec, a top female bariatric surgeon and founder of BodyByBariatrics, to break down the decision between bariatric surgery vs GLP-1 medications from the perspective of someone who treats patients with both options every day. Dr. Dovec explains what gastric bypass surgery involves, why some patients go home the same day, and who may be an ideal candidate.The conversation then turns to GLP-1 weight loss medications. Amy and Dr. Dovec compare Ozempic and Zepbound, the often-overlooked side effects, and explain why weight regain is common after patients stop taking these medications. Dr. Dovec also shares why some post-surgery patients respond well to GLP-1 medications and how the combination may help support their long-term results.For women in midlife, this episode examines how GLP-1 medications may fit into treatment for weight gain during perimenopause and menopause. Dr. Dovec explains why the habits you once relied on may become less effective as your hormones shift. She also discusses the health risks associated with visceral fat and the potential role of GLP-1 treatment in reducing the internal fat linked to heart attacks, strokes, and fatty liver disease.If you have tried every diet and still feel stuck, this conversation about bariatric surgery and GLP-1 medications offers a clearer framework for understanding your options.Episode Breakdown:00:00 Meet Bariatric Surgeon Dr. Betsy Dovec01:28 What Gastric Bypass Surgery Actually Involves04:55 Who Qualifies as a Bariatric Surgery Candidate06:30 Bariatric Surgery vs GLP-1 for Long-Term Success09:37 Why GLP-1 Medications Are a Hot Topic10:57 Semaglutide and Tirzepatide Dosing Explained13:34 Same Drug Different Label for Diabetes and Weight Loss15:54 Oral GLP-1 Pills and What Comes Next17:25 Brand-Name vs. Compounded GLP-1 Medications21:13 GLP-1 Benefits During Perimenopause and Menopause23:13 Breaking the Stigma Around GLP-1 Use27:26 Visceral Fat Differences in Men and Women30:55 Sugar, Fatty Liver, and Visceral Fat Risks32:56 How Surgery and GLP-1 Both Reduce Visceral Fat36:40 Inside the OR Surgery Time and Recovery38:38 Dr. Dovec's Beauty and Self-Care Routine48:07 Where to Find Dr. Betsy DovecConnect with Dr. Betsy Dovec:Follow Dr. Dovec on InstagramVisit the BodyByBariatrics WebsiteFollow BodyByBariatrics on TikTok⁠⁠⁠⁠For More on this Episode: Read the full show notes ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠

(00:00:00) 224: DOCs Itchy&Bitchy Answer YOUR Questions - Global Edition! (00:00:11) Welcome to Itchy and Bitchy (00:00:42) Doc Itchy Medical Pets Supplements (00:02:32) Hormone Replacement and GLP-1: Navigating Medical Decisions (00:08:06) Brain Fog and Alzheimer's: When to Worry (00:11:11) Menopause in Dogs: A Misunderstanding (00:16:48) The Truth About Alcohol Consumption (00:22:10) GLP-1 and Addiction: A Complex Discussion (00:27:41) Probiotics: The Unknown Frontier (00:32:05) Closing Thoughts on Supplements and Health Ask Docs Itchy&Bitchy:Your Questions on Weight, Hormones, and the GLP-1 additction ...You're writing in from everywhere, and your questions don't hold back, so neither will we. Why is your dog carrying extra weight even though nothing about mealtime has changed? On the human side: does Ozempic actually rewire your brain's reward system, not just your appetite? Emerging research says GLP-1 drugs quiet the same dopamine pathway that drives cravings for food, alcohol, and drugs which raises a wild question we're tackling this season: could a diabetes drug end up treating addiction? We're also digging into whether "Ozempic personality changes" are real, why weight-loss drugs hit women differently at midlife, and what nobody's telling you about pet supplements.Got a question? Send it — nothing's off limits.Visit itchyandbitchy.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/itchy-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system.  From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too.  For chronic illness warriors, self-advocacy seekers: WE OFFER  No BS 

In this episode, I'm joined by board-certified OBGYN and integrative medicine physician Dr. Shawn Tassone to break down one of the fastest-growing topics in health today: peptides. We discuss what peptides are, how they work in the body, and why they've become so popular for everything from weight loss and longevity to muscle recovery and inflammation. We also take a closer look at some of the most talked-about peptides, including semaglutide, tirzepatide, BPC-157, MOTS-c, tesamorelin, and more, discussing the current research, potential benefits, safety concerns, and which ones may actually be worth considering. If you've ever wondered whether peptides are the future of medicine or simply the latest health trend, this episode is for you!

Is Ozempic secretly slowing down your thyroid? Millions are using GLP-1 medications like Ozempic for weight loss and blood sugar control, but very few people are being warned about what they could be doing to their thyroid health.If you're experiencing fatigue, hair loss, brain fog, cold hands and feet, constipation, or stubborn weight loss plateaus after starting Ozempic, your thyroid may be sending you warning signs that are often overlooked.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the surprising connection between Ozempic, GLP-1 medications, and thyroid function, why standard thyroid testing may miss the problem, and the essential nutrients your thyroid needs to function properly.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, this is information you don't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

In this episode of Girl Talk with Tay, I sit down with Bracha Banayan, family nurse practitioner, entrepreneur, and founder of IVDrips and Hello Dose, for one of our most fascinating conversations yet. We dive into the science behind GLP-1 medications, why they're about so much more than weight loss, and how they're changing the conversation around longevity, metabolic health, and healthy aging.Bracha explains how GLP-1s work in the body, why weight gain is often rooted in biology rather than willpower, and how factors like glucose, insulin, inflammation, and hormones all play a role in long-term health. We also discuss who may benefit from GLP-1 medications, including women navigating perimenopause and menopause, adults focused on cardiovascular health, and those looking to improve metabolic wellness.We also get into fertility, blood sugar, continuous glucose monitors, and the surprising ways GLP-1s may help reduce cravings by working on the brain's reward system. Beyond medications, Bracha shares the foundational habits she believes everyone should prioritize first from walking after meals and getting morning sunlight to improving sleep and building sustainable wellness routines.Whether you're curious about GLP-1s, trying to better understand metabolic health, or looking for practical ways to optimize your health for the long run, this episode is packed with insights and actionable takeaways.xo, Tay⸻Follow Bracha Banayan!

Before EP Description: Learn about the Healing Power of Prolonged Fasting: HEREWhat if losing weight on a GLP-1 drug and losing weight through fasting produce the same number on the scale, but nearly opposite effects inside your cells?Host Dr. Katie Deming believes some of the most popular weight loss drugs on the market may be quietly blocking one of your body's most essential repair processes. Not because they're failing to work, but because they work in a way that keeps your body in a state it was never meant to stay in.She takes an honest, no-shame look at GLP-1 drugs like Ozempic and Wegovy and compares what's actually happening inside your body when you lose weight on them versus when you fast. The scale might show the same number. The story underneath is very different. Dr. Katie explains a repair switch your body can only flip when your stomach is genuinely empty, and why keeping it perpetually fed may keep that switch turned off for good. She connects the dots between mitochondrial health, cellular cleanup, visceral fat, muscle preservation, and metabolic flexibility in a way that's clear, honest, and direct.She's not here to shame anyone taking these medications. She gets why people reach for something that works. But she shares what happened when several of her patients who were certain they'd go right back on the drug after fasting decided they didn't want to, and why.Chapters:00:04:23 - The Food System Is Broken00:06:13 - Your Body Needs Empty Space00:08:24 - GLP-1s May Block Repair Mode00:10:41 - Weight Loss Is Not Healing00:12:26 - What Cancer Cells Feed On00:13:30 - Fasting Changes the Terrain00:17:00 - Cleaning Out Damaged Mitochondria00:18:00 - The Most Dangerous Fat00:20:35 - The Hidden Muscle Loss Problem00:22:20 - Clients Who Were on GLP-1s Before Fasting00:26:06 - Who Should Never Water Fast If you've ever wondered whether weight loss and true healing are actually the same thing, or why one of her patients gained lean mass six weeks after a 14-day water fast, this episode will change how you think about what your body actually needs.Press play and learn why the repair process your body is waiting to run may only start when you finally stop feeding it.Join Dr. Katie's 3-Day Guided Fast, for expert support, daily live calls, and a community to fast alongside: Sign-Up Follow Dr. Katie Deming on InstagramWatch on YoutubeDISCLAIMER: The Born to Heal Podcast  is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.A thought-provoking podcast explores cancer through the lens of holistic medicine and functional medicine, discussing causes of cancer, metabolic health, and unconventional approaches like water fasting, fasting and autophagy, and detox, while weighing fasting benefits against chemo side effects and radiation side effects, sharing stories of a cancer survivor navigating chemotherapy, natural medicine, holistic healing, and even spiritual healing on the path toward cancer remission and holistic health. 

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available for people with type 1. In this special episode, Dr. Neil Skolnik speaks with Janet McGill, MD, MA, FACE, FACP about the underdiscussed prevalence of CKD in type 1 and the importance of continued development in this area. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine at the University of Washington's John T. Milliken Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research Selected References: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.

On today's Good Day Health Show - ON DEMAND…Dr. Jack Stockwell, a NUCCA Chiropractor and GAPS Practitioner in SLC, UT (866.867.5070 | ForbiddenDoctor.com | JackStockwell.com), shares a holistic perspective on health news today. Dr. Jack offers an insightful discussion challenging common beliefs about cholesterol, aging, and the role nutrition plays in maintaining long-term health. Dr. Jack examines widespread misconceptions surrounding cholesterol, explaining why it is an essential component of the body and discussing research suggesting that excessively low cholesterol levels—particularly in older adults—may be associated with certain health risks. The conversation explores the relationship between cholesterol and healthy aging, while encouraging listeners to better understand cholesterol's many functions beyond cardiovascular health.The episode also takes a closer look at the growing use of GLP-1 weight-loss medications, including Ozempic, and discusses concerns about their potential impact on connective tissue, muscle mass, and overall body composition during significant weight loss. Dr. Jack emphasizes the importance of supporting connective tissue through proper nutrition, adequate protein intake, essential nutrients, and healthy lifestyle habits that promote strength, mobility, and resilience as we age.Throughout the discussion, Doug and Dr. Jack examine how nutrition, inflammation, and lifestyle choices influence the aging process and overall wellness. They also explore the role the medical industry has played in shaping public perceptions of cholesterol and heart health, encouraging listeners to consider a broader perspective when evaluating their own health decisions. The episode concludes with practical strategies for supporting connective tissue health naturally, providing listeners with actionable insights for maintaining strength, mobility, and overall well-being throughout every stage of life.For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

Thinking about starting Ozempic for weight loss or type 2 diabetes? Already taking it and wondering if you should stop? Before making any decision, listen to this important information.In this episode of Accelerated Health with Sara Banta, I break down the science behind Ozempic, how it works, who may benefit from it, the potential risks of stopping too soon, and what you should know before beginning treatment. You'll also learn why addressing your overall metabolic health is essential for long-term success—not just relying on medication alone.Whether your goal is healthy weight loss, improving blood sugar, or understanding the pros and cons of GLP-1 medications, this episode provides practical insights to help you make informed decisions with your healthcare provider.If you're considering Ozempic, Wegovy, or other GLP-1 medications, this is an episode you won't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast®  https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

In this podcast, Jennifer Green, MD, and Jay H. Shubrook, DO, FAAFP, FACOFP, share strategies for integrating incretin-based therapies in type 2 diabetes (T2D) management in the primary care setting, including: Importance of moving beyond a glucose-centric approach to T2D care  Current evidence for incretin-based therapies in T2D Rationale for integrating these therapies into the primary care setting Shared decision-making strategies to discuss optimal T2D treatment options with patients Timing for endocrinology referral Presenters: Jennifer Green, MD Professor of Medicine Division of Endocrinology Duke Clinical Research Institute Duke University School of Medicine Durham, North Carolina Jay H. Shubrook, DO, FAAFP, FACOFP Professor, Diabetologist Department of Clinical Sciences and Community Medicine Touro University California, College of Osteopathic Medicine Vallejo, California Full program link: https://bit.ly/4uSKCqv Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Adding a cash-pay service to an insurance-based practice may seem like a simple way to grow revenue, but it can introduce significant compliance risk. This fan-favorite episode explores how a cardiology practice's weight loss program created patient confusion, operational headaches, and unexpected legal exposure. Tune in for compliance considerations to keep in mind when blending payment models.Chapters[00:00] Intro[1:12]  Banter  [06:08]  Story  [16:02]  Access+  [16:38]  Legal Takeaways  [29:05]  OutroWatch full episodes of our podcast on our YouTube channel: https://www.youtube.com/@byrdadattoStay connected for the latest business and health care legal updates:WebsiteFacebookInstagramLinkedIn

Get Pep'd published a guide separating semaglutide peptide terminology from research-product listings, powder claims, compounded labels, and provider-reviewed care paths. Get Pep'd City: Kalispell Address: 1001 S Main St Website: https://getpepd.com Phone: +1 415 619 7661 Email: bryan@getpepd.com

The World Cup is here, and while we watch some of the world's greatest athletes competing on a global stage, it's fascinating to consider what effect this intense activity may have on the human body. With that in mind, we're re-releasing our conversation with Stanford biochemist Jonathan Long on the future of exercise. Jonathan studies the chemistry of what happens inside your body when you move, and his findings are pointing toward some genuinely surprising possibilities — including treatments for obesity, diabetes, and even, someday, an exercise pill. If the athleticism on the pitch has you feeling inspired, this one is well worth another listen. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Jonathan Long Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Jonathan Long, a professor of pathology from Stanford University. (00:02:02) Effective Weight Loss Drugs The history and development of GLP-1 receptor agonists. (00:04:04) Understanding Metabolism and Exercise Why Long's lab starts with molecules to understand metabolism and physical activity. (00:05:10) Animal Models in Exercise Studies The use of animal models in exercise studies and the discovery of Lac-Phe. (00:06:47) Psychological Preparation for Exercise The psychological aspects of exercise and the involvement of endocannabinoids in exercise motivation. (00:09:00) Lac-Phe's Role and Mechanism The role of Lac-Phe and its production in the gut. (00:12:08) Differences in Exercise Response Differences in exercise response between trained athletes and untrained individuals. (00:12:57) Diabetes and Metabolic Diseases The relationship between diabetes, exercise, and metabolic diseases. (00:15:01) Lac-Phe as a Potential Therapeutic The potential of Lac-Phe as a weight loss drug, and parallels to GLP-1 drug development. (00:16:21) Importance of How Weight is Lost Whether the method of weight loss matters, and the importance of preserving lean muscle mass. (00:18:37) Exercise as Medicine The concept of exercise as medicine, and defining physical activity at the same resolution as modern medicines. (00:22:11) Metformin and Exercise Pathways The unexpected connection between metformin and the Lac-Phe pathway. (00:24:01) Prospects of an Exercise Pill The future of an exercise pill, and the challenges associated with its development. (00:27:05) Conclusion Final thoughts on the future of exercise. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Could Ozempic impact breast cancer risk? Are the alarming headlines telling the full story? In this eye-opening episode of the Accelerated Health with Sara Banta, I explore the latest discussions surrounding Ozempic, GLP-1 medications, and breast cancer concerns.Discover what current research says, the potential benefits and risks of these popular weight-loss and diabetes prescriptions, and why understanding the science behind the headlines is essential for making informed health decisions. If you're considering Ozempic, currently taking it, or simply want to stay informed about the latest health trends, this episode provides valuable insights you won't want to miss.Listen now and empower yourself with knowledge that could impact your health and wellness journey. Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement  • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated AMINOS® https://www.acceleratedhealthproducts.com/products/accelerated-aminos Not sure what food to eat and avoid? This guide is for you.⬇️

Inside the venom of a desert lizard, scientists found a molecule that does something the diet industry spent 50 years failing to do. It quietly switches off hunger. That molecule is now the most talked about drug on the planet, and it's sitting in the fridges of millions of people who couldn't explain how it works if you paid them.Dr Tom Buckley, 30 years in medicine and a professor at Sydney University, has looked at the evidence and called these drugs revolutionary.But what about "Ozempic face"? What if the wait comes back after you stop? Who should never touch these drugs? Dr Tom and Andrew get into the science so you finally have all the answers you need. 00:00 – A desert lizard that eats twice a year 03:32 – What a GLP-1 actually is, in plain English 07:36 – Ghrelin and leptin: hunger and fullness, explained 10:23 – The venom that cracked the hunger code 14:06 – Why your body is built to hold onto fat 15:19 – How to raise GLP-1 without a prescription 18:10 – Become the CEO of your body and brain 22:10 – You don't lose fat cells, they shrink 24:39 – "Ozempic face," and why you lose weight slowly 28:17 – The "Limitless" effect: cognitive horsepower 29:28 – 76 trials, 40,000 patients: the evidence 30:47 – Lancet 2024: heart attacks and strokes down 32:11 – Why Tom calls these drugs regenerative 34:18 – Who should never take it 35:23 – The side effects nobody mentions upfront 41:19 – On it and off it: what you have to get right 48:14 – Most regain 75% within a year of stopping 50:09 – Metabolic rebound: worse than where you started 52:51 – The hidden economy GLP-1s are reshaping 56:13 – Tom's cliff notesYou can find Dr Tom at his LinkedIn: https://www.linkedin.com/in/tom-buckley-06a76b98/ Use Code "PQPODCAST10" to get 10% off your Lumo Coffee order:https://lumocoffee.com/ Interested in sharing your story? Email Producer Shannon at support@performanceintelligence.com today with your story and contact details. Learn more about Andrew and Performance Intelligence: https://performanceintelligence.com/Find out more about Andrew's Keynotes : https://performanceintelligence.com/keynotes/Follow Andrew May: https://www.instagram.com/andrewmay/Watch the Performance Intelligence Podcast on Youtube: https://www.youtube.com/@performanceintelligencepodcastIf you enjoy the podcast, we would really appreciate you leaving a short review on Apple Podcasts, Spotify or Google Play. It takes less than 60 seconds and really helps us build our audience and continue to provide high quality guests.

GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured:  Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University 

Semaglutide. Tirzepatide. Retatrutide. The peptide conversation has taken over every gym, group chat, and social media feed. But the part about muscle loss, osteopenia, and what the gray market is actually selling you? That part is getting buried. Chalene Johnson sits down with Adam Schafer, co-host of Mind Pump, one of the top fitness podcasts in the world with nearly half a billion downloads. Adam spent three and a half years running real test groups on GLP-1s including Ozempic and Wegovy. What he found changed his perspective entirely and he is not holding back. This conversation covers what is actually driving muscle and bone density loss in women over 40 and 50, why the scale and the mirror are lying about body composition, and what most women are getting wrong about building real strength in midlife. Plus the truth about the gray market and what those peptides may actually contain. This is the conversation the fitness industry is not having and it is one every woman over 40 needs to hear.

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

GLP-1 stopped working? Or is your body trying to tell you something deeper?In this episode, Kylie unpacks the REAL reason so many women hit a weight loss plateau while taking Ozempic, Mounjaro, Semaglutide or Tirzepatide… and why the answer is NOT always “eat less” or “increase your dose.”You'll learn: • Why GLP-1 plateaus happen • The hidden danger of losing muscle while dieting • How chronic stress and cortisol can stall fat loss • Why blood sugar regulation matters more than calories alone • The truth about “metabolic damage” • How under-eating protein can slow your progress • Why your nervous system affects the scale more than you think • The biggest mistakes women make when their appetite drops • How to support your metabolism WITHOUT spirallingThis episode is a must-listen for women over 40 who feel frustrated, stuck, inflamed, exhausted, or scared that their body has “stopped responding.”Because your body isn't broken, babe. It's adapting.And once you understand what's really happening beneath the surface… everything changes.

How fast does semaglutide work? The short answer is that many people will lose weight in the first week of taking semaglutide if they make lifestyle changes (e.g., increased physical activity and reduced-calorie diet). Remember, the first 4 doses are small and are primarily used to gently introduce the peptide to the body without risking stomach-related side effects. It's important to understand that it's possible to "out-eat" any weight loss medication. So, you may see little to no weight loss in the early weeks without making lifestyle changes.  Read the Full Episode Transcript: https://pepties.com/faqs-about-semaglutide/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Buy Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

Nutritionist Leyla Muedin discusses research showing simple strength tests—grip strength and a five-rep sit-to-stand chair test—predict longevity in older women. In a University at Buffalo study of over 5,000 women ages 63–99 followed for eight years, stronger grip and faster chair-stand times were linked to lower mortality; every additional 7 kg of grip strength corresponded to a 12% reduction in death risk, and faster chair-stands were also associated with improved survival, even after adjusting for activity, cardiovascular fitness, and inflammation. She emphasizes prioritizing muscle-strengthening alongside aerobic exercise and suggests accessible resistance options (weights, bodyweight moves, or household items) with professional guidance as needed. She then cites UK Biobank data linking long-term statin use to declines in grip strength and appendicular lean mass, urging discussion with physicians and added vigilance, especially for those also using GLP-1 drugs that may reduce protein intake and muscle mass.

What if the newest “miracle” weight loss prescription is hiding the SAME root problem as Ozempic?Retatrutide is being called the next-generation fat loss breakthrough… promising even MORE dramatic results than Ozempic. But before you jump on the hype, there's something no one is talking about.Could rapid weight loss come at the expense of your metabolism, muscle mass, hormones, and long-term health?Watch until the end before deciding if Retatrutide is really “better.” Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement  • Accelerated Methylene Blue® https://www.acceleratedhealthproducts.com/products/accelerated-methylene-blue-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast® https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Cellular Detox® Powder https://www.acceleratedhealthproducts.com/products/accelerated-cellular-detox-powderNot sure what food to eat and avoid? This guide is for you.⬇️

Can topical B12 help relieve itching?The types of doctors to avoidGetting back to basicsA case study of lavender oil helping to relieve itchingYou say you're dairy sensitive but you use whey protein. Please explain.What are your thoughts on a lactose relief patch that is on offer?

Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Update: Shah S, et al. "Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort Diabetes Care. 2026;49(6):1067–1077. doi.org/10.2337/dc25-2727 Hespanhol L, et al. "Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Diabetes Care. 2026;49(6):1134–1143. doi.org/10.2337/dc25-2435 Tatum K, et al. "Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer." JAMA. Published Online: May 11, 2026 2026;9;(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133 Winkler C, et al. "Screening Children for Early-Stage Type 1 Diabetes." JAMA. Published Online: May 21, 2026 doi:10.1001/jama.2026.6085 Würtz Yazdanfard P, Kosjerina V, Wood-Kurland H et al. "Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)" Lancet. Volume 66, 101716, July 2026. doi:10.1016/j.lanepe.2026.101716 Horn D, Aronne L, Wharton S et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial." Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2 Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

Taylor and I are back for another Reader Mailbag. This one covers a lot of ground.We start with anhedonia on GLP-1s because the questions on this have been nonstop. People are experiencing it on Semaglutide, Tirzepatide, and Retatrutide and we break down why it happens, whether it is dose related, and what you can actually do about it.From there we get into the Reta and heart rate debate, Taylor's GLP rotation strategy, and whether the cardiovascular tradeoffs are actually worth worrying about.Then Taylor takes over for the hormone optimization section for young women in their twenties and thirties. Her personal story on this one is worth watching alone.We also cover accidental peptide overdoses, what to do when it happens, and finish with teen acne solutions using peptides and topicals.Submit your questions for the next episode at the link below.For research and entertainment purposes only.Links, cheatsheet, private group and more

In this episode, we break down the science behind GLP-1 medications including Ozempic, Wegovy, Zepbound, Mounjaro, semaglutide, and tirzepatide. Learn how GLP-1 weight loss medications work, their role in appetite suppression, insulin regulation, metabolic health, obesity treatment, and type 2 diabetes management.This evidence-based discussion explores GLP-1 benefits, side effects, muscle loss concerns, weight regain after stopping medication, nutrition considerations, digestion, metabolic adaptation, and sustainable wellness strategies. If you're considering GLP-1 medications or simply want a smarter conversation about obesity medicine, weight loss, longevity, and metabolic health, this episode delivers a clinically grounded wellness perspective. Disclaimer: This podcast is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The views shared are intended to support informed wellness conversations and should not replace individualized guidance from your physician or qualified healthcare provider. Always consult your healthcare team before making decisions regarding medications, treatment, nutrition, or health management.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates offer a fascinating glimpse into an industry marked by dynamic shifts and groundbreaking advancements, each promising to reshape the future of healthcare. Let's delve into some of the most notable developments that are capturing attention across the globe. Starting with Eli Lilly's obesity medication, Zepbound, which has regained insurance coverage through CVS Caremark. This decision is emblematic of a broader recognition of obesity as a significant health issue that demands comprehensive treatment solutions. The reinstatement of coverage enables more patients to access Zepbound, potentially setting a benchmark for other insurers and leading to improved health outcomes. Shifting focus to oncology, AbbVie has secured FDA approval for a new therapy derived from its acquisition of ImmunoGen, adding to its portfolio of antibody-drug conjugates (ADCs) with Elahere. This development underscores the escalating value of ADCs in precision cancer therapies, offering innovative solutions for targeting cancer cells while preserving healthy tissues. Japan's pharmaceutical R&D stance is under examination as Prime Minister Sanae Takaichi meets with over 20 industry leaders to discuss maintaining the nation's competitive edge. This gathering highlights a global race among nations to enhance their R&D capabilities, ensuring leadership in pharmaceutical innovations. In neuroscience, Novartis's relentless pursuit to conquer the blood-brain barrier reflects ongoing efforts to revolutionize treatments for neurological disorders. Despite recent advancements, Novartis continues to explore new strategies for drug delivery to the brain, aiming to unlock therapies for conditions like Alzheimer's and Parkinson's disease. Viridian Therapeutics' collaboration with Wuxi Biologics marks a notable push in the eye drug market, positioning them against major players like Amgen. This partnership emphasizes manufacturing capability as a critical factor in ensuring resilient supply chains and competitive advantage. The hepatitis B treatment landscape has witnessed significant progress with GSK's phase 3 trial results for its drug Bepirovirsen. Achieving a functional cure in around one-fifth of patients signifies a major step forward in addressing this widespread disease. The potential to reduce lifelong antiviral therapy and lower liver cancer rates illustrates the transformative impact of nucleic acid-based therapies. Leadership dynamics also play a crucial role in pharma strategies. PharmaEssentia's appointment of Eric Vogel highlights the industry's reliance on seasoned talent to drive market expansion and broaden therapeutic indications, particularly for its rare blood cancer drug Besremi. In longevity research, Human Longevity's collaboration with Insilico Medicine introduces Human Life Foundation Models (HLFM), leveraging AI and genomics to extend human lifespan. This initiative is part of a broader trend integrating cutting-edge technologies into healthcare research, reflecting an evolving focus on longevity and genomic sciences. Regulatory landscapes are also evolving, as seen with CMS finalizing changes to the No Surprises Act dispute resolution process. By streamlining arbitration amidst rising disputes, these updates aim to refine healthcare policy frameworks for more efficient stakeholder service. Meanwhile, biosimilar approvals are gaining traction globally. ANVISA's approval of EMS's Ozivy in Brazil introduces a cost-effective alternative to Novo Nordisk's semaglutide (Ozempic) for type 2 diabetes. This step enhances access to affordable diabetes treatments, crucial for managing this prevalent metabolic disorder. In clinical trials innovation, D&D Pharmatech's Zabopegdutide has shown promising Phase 2 results for metabolic dysfunction-associated steatohepatitis (MASH), indicating fibrosis improvement and potential disease resolution. These findings underscore dual receptor agonists' therapeutic promise in tackling complex metabolic conditions. Additionally, Kailera Therapeutics' KAI-4729 demonstrates significant weight loss in Phase 1 obesity trials, potentially reshaping the obesity treatment landscape by offering superior weight management options compared to existing therapies. Funding rounds like Secretome Therapeutics' successful $30 million Series A highlight ongoing investments in regenerative medicine and cell-based therapies, propelling advancements in cardiovascular disease treatment pipelines. The acquisition landscape remains active with CordenPharma's purchase of AmbioPharm, expanding peptide manufacturing capabilities across U.S. and China markets. This move meets growing demand for peptide APIs vital in drug development processes. Technological innovation remains pivotal as Biohub releases an AI World Model for protein biology to expedite therapeutic discovery processes. This tool exemplifies computational biology's integration into drug discovery efforts, enhancing efficiency and innovation. Overall, these developments illustrate a vibrant pharmaceutical and biotech landscape characterized by scientific breakthroughs, strategic partnerships, regulatory achievements, and technological advancements—all aimed at advancing patient care and expanding therapeutic possibilities across diverse medical domains. As these trends continue unfolding, they promise not only improved treatment outcomes but also a more robust global healthcare ecosystem committed to innovation and excellence. Thank you for tuning into Pharma Daily; stay informed as we continue bringing you the latest from this rapidly evolving industry.Support the show

I am happy to connect with Dr. William Li today! He is a world-renowned physician, scientist, speaker, and author. He is known for leading the Angiogenesis Foundation, and his groundbreaking work has impacted more than 70 diseases. He is also a Ted-X speaker and the author of Eat to Beat Your Diet, one of my favorite books thus far this year.  Dr. Li's latest book is about what happens in the body, how it should operate, and the steps we can take to restore it to its hard-wired state. We dive into how body fat impacts our health, the role of metabolism throughout our lifetime, the differences between the three fat-impacting hormones, including leptin, adiponectin, and resistin, and gender differences. We speak about new drugs like Ozempic and Semaglutide, the role of brown fat, the impact of the microbiome and specific bacteria, and nutrition and lifestyle. IN THIS EPISODE YOU WILL LEARN: Why Dr. Li chose this time to write his latest book  Is 60 the new 20? The four stages of metabolism hardwired into each of us  How excess body fat derails metabolism, and how can we unleash our inner metabolism Why is it better to eat slowly? Why should we learn to respect and tame our fat instead of hating or fearing it? Dr. Li shares his views on new prescription drugs like Ozempic and Semaglutide. Interesting facts about body fat Changes that occur in our body fat distribution as we get older How can we help our bodies fight excess body fat, bring our inner metabolism to the surface, and reduce inflammation by being aware and mindful? Modern-day lifestyle choices and metabolic disease Dr. Li discusses the interplay between the gut microbiome and metabolism, as well as the role of Akkermansia.  Some everyday foods contain natural chemicals that can activate our body's defenses, tame metabolism, and fight body fat. BIO William W. Li, MD, is an internationally renowned physician, scientist, and New York Times bestselling author of the forthcoming book “Eat to Beat Your Diet: Burn Fat, Heal Your Metabolism, Live Longer”. His groundbreaking work has led to the development of more than 30 new medical treatments and impacts care for more than 70 diseases, including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, “Can We Eat to Starve Cancer?” has garnered more than 11 million views. Dr. Li has appeared on Good Morning America, CNN, CNBC, LIVE with Kelly and Ryan, and the Rachael Ray Show, and he has been featured in USA Today, Time Magazine, The Atlantic, and O Magazine. He is the president and medical director of the Angiogenesis Foundation. Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Dr. William Li On his⁠ website⁠ Social media: @DrWilliamLi Dr. William Li's latest book, ⁠Eat to Beat Your Diet: Burn Fat, Heal Your Metabolism, and Live Longer⁠ is available from most bookstores.

Highlights from Dr. Hoffman's Scandinavian tripShould I eliminate the nightshade family of foods from my diet?My friend has been experiencing acid reflux since using a reverse osmosis water filtration system

Book a free consultation call with Robert Sikes to break through your keto or low carb plateau right here: https://www.ketobodybuilding.com/callSurviving childhood morbid obesity and a fifteen year meth addiction takes total metabolic repair. In episode 886 of the Savage Perspective Podcast, host Robert Sikes sits down with Elaina Wang to share a powerful story of survival and deep health recovery. This discussion reveals how severe insulin resistance and bad food rules created a massive drug habit just to feel energy. Getting clean from drugs was brutal, but finding the keto diet and reversing type two diabetes naturally changed her entire life. You will learn exactly how real nutrition, heavy weight lifting, and targeted peptides can heal your brain, stop cravings, and fix chronic pain after years of severe trauma and addiction.Elaina's Hack Your Health Coaching: https://hackyourhealthcoaching.com/elaina-wangElaina's FB: https://www.facebook.com/KetoWang/Get Keto Brick: https://www.ketobrick.com/Subscribe to the podcast: https://open.spotify.com/show/42cjJssghqD01bdWBxRYEg?si=1XYKmPXmR4eKw2O9gGCEuQChapters0:00 - How I Survived Childhood Obesity & Severe Insulin Resistance1:09 - Why I Started Meth: The Shocking Truth About Energy & Fatigue2:01 - The Food Pyramid Myth: How Government Guidelines Fueled Addiction3:47 - Unbreakable Confidence: How to Build Self-Esteem When Overweight6:14 - The "Fat Meth Addict": Why Stimulants Couldn't Fix Type 2 Diabetes8:17 - Meth vs Cocaine: How Drugs Hijack Brain Dopamine & Sugar Cravings11:08 - The Secret Life of a Functional Addict: Survival Tactics & Thefts13:36 - Toxic Relationships: Navigating Co-Dependency & Addiction Relapse17:03 - The Turning Point: Dodging the Cops & Deciding to Get Clean20:43 - Type 2 Diabetes Diagnosis at 24: Ignoring the Ultimate Warning Sign21:10 - Quitting Meth Cold Turkey: The Brutal Reality of Early Sobriety25:22 - Blood Sugar at 426: Why I Refused Insulin Due to Addiction Fears27:08 - Reversing Type 2 Diabetes Naturally with the Keto Diet28:24 - Keto & Neuroplasticity: The Ultimate Biohack for Addiction Recovery30:02 - Losing 80 Lbs Fast: Do Cigarettes Spike Your Blood Sugar?34:00 - Becoming a Keto Coach: The Evolution of Low-Carb & Carnivore Diets36:10 - Healing Trauma vs. Trauma Bonding: The Missing Link in Weight Loss41:17 - BPC-157 & TB-500: Can Peptides Cure Chronic Pain & Bursitis?45:13 - GLP-1 for Addiction: The Unbelievable Cure for Alcoholism & OCD49:02 - Semaglutide vs Tirzepatide: Which GLP Weight Loss Peptide is Best?51:49 - The Dark Side of Ozempic: Who Should NEVER Take GLP Peptides53:31 - 155 Lb Weight Loss Surgery: Is Medical Tourism in Tijuana Safe?57:11 - Tummy Tuck Complications: Hematomas, Wound Vacs & Honest Recovery1:01:01 - "Am I Too Old to Get Healthy?" The Ultimate Mindset Shift for Men & Women1:05:26 - Where to Find Elaina Wang: Coaching, Biohacking & Future Events

Dr. Mindy talks about Crab Boils. And then she answers questions about numb tongue, why do men age so well, tennis elbow, Adderall, side effects of Semaglutide, how many grams of fiber do you need, NAD formulations, allergy headaches, blurred vision with Tirzepatide, lump on a toddler's chin, ice cold feet, another Adderall question, grey hair, tally-whackers and loud tummy noises. https://www.youtube.com/@TheDrMindyExperiment See omnystudio.com/listener for privacy information.

Peptides are everywhere right now but most people still don't understand how they actually work.In this episode of Under Contract, we sit down with Dr. Gabriel Alizaidy to break down the science behind peptide therapy, GLP-1 medications, if retatrutide works for weight loss, recovery stacks, and the truth about biohacking trends dominating social media.We discuss how peptides can support weight loss, inflammation, healing, hormone balance, mitochondrial health, longevity, and performance, but also why most people are using them incorrectly.Topics include: • GLP-1 medications like Semaglutide and Tirzepatide • Why peptide therapy should be medically supervised • The “Wolverine Stack” for recovery: BPC-157 + TB-500 • Copper peptides and the “copper uglies” explained • Peptides for sleep, fat loss, muscle retention, and high performance • Hormones, mitochondria, and why bloodwork matters before starting • Common peptide mistakes people make from TikTok advice • Longevity, anti-aging, and optimizing your health safelyIf you're curious about GLP-1s, peptide stacks, anti-aging protocols, or how peptides are changing medicine, this conversation breaks down what's real, what's hype, and what to know before trying them.Connect with Dr. Alizaidy on Instagram: @gabrielalizaidy#Peptides #GLP1 #Biohacking #Longevity #WeightLoss #HormoneOptimization #AntiAging #Recovery #HealthPodcast #WellnessPodcast

Nutritionist Leyla Muedin discusses a listener question about whether agave nectar can contribute to obesity like high-fructose corn syrup, arguing that regular use of sweeteners—including agave, honey, monk fruit, stevia, aspartame, sucralose, allulose, and sugar alcohols—can maintain sweet cravings, spike insulin, and contribute to weight-loss plateaus, with added concerns such as microbiome effects, GI upset, and aspartame's neurotoxicity. She notes insulin's role in fat storage and blood pressure via sodium retention, and suggests that needing a sweetener in coffee or tea may indicate dependence on sweetness. She then covers a newly developed, validated Food Noise Questionnaire (FNQ) published in Obesity to measure intrusive food-related rumination, highlighting its five Likert-scale items, study sample characteristics, and the need for further research, including effects of GLP-1 drugs.

More on “eat the rainbow” . . . or notMedical breakthroughs that we don't really needCan you discuss the order of eating macronutrients and its impact on blood glucose?What about the impact of apple cider vinegar on blood sugar?

Are GLP-1 medications like Semaglutide, Tirzepatide, and Retatrutide helping or hurting your recovery? In this episode I cut through the hype and fear to talk about the real dangers people aren't discussing, how these medications should actually be used, and why no tool can replace healing your relationship with food. If you're considering a GLP or already using one, this is an important conversation you need to hear.Grab your copy of my FREE 9 page Beginner's Guide to Food Sobriety https://www.foodfreedomwithmary.com/foodsobrietyguideFood Freedom Online Course: https://www.foodfreedomwithmary.com/foodfreedomcourseFood Sobriety Mini Course -https://www.foodfreedomwithmary.com/foodsobrietymcWant to learn more about me and my coaching programs? Do you need private coaching and intensive daily contact with a coach? Fill out my application so we can chat about whether or not my program is for you and which option is best for you. Payment plans available. Don't see a payment option that works for your pay schedule? Let's chat about a custom pay plan.www.foodfreedomwithmary.com/chooseyourpath Join my online community The Food Freedom Tribe! An online community of support, eduction, inspiration, accountability….. Learn more here: https://www.foodfreedomwithmary.com/tribemembership Application: https://docs.google.com/forms/d/1upnWHYK0RXfmyRTqlsF_R06z3NA8LZYHIMWFykq7-X4/viewformInstagram: www.instagram.com/coachmaryroberts Facebook: www.Facebook.com/ketomary71 Facebook group: https://www.facebook.com/groups/4915319108493196/?ref=share_group_linkWebsite: www.foodfreedomwithmary.com Join the email list.Email: mary@foodfreedomwithmary.com

Could the "weight-loss shots" everyone is talking about actually be the next big breakthrough in cancer prevention? In this week's episode of the FMI podcast, I'm joined once again by our Chief Medical Officer, Dr. Mark Holthouse. While Dr. H is a world-renowned expert in hormone health and cardiometabolic medicine, today we are diving into a topic that is reshaping the future of longevity: the direct link between obesity-related cancers and GLP-1 medications. We recently learned that colon cancer is now the leading cause of cancer death for men and women under 50. It's a sobering statistic, but there is hope in the evolving science of metabolic medicine. In this episode, we discuss: The "Four Horsemen" of Aging: Why cardiovascular disease, cancer, dementia, and insulin resistance are all driven by the same cellular pathways. GLP-1s Beyond Weight Loss: How medications like Semaglutide and Tirzepatide work at the cellular level to potentially reduce tumor volume and progression. The "New Kid on the Block": A deep dive into Retatrutide, the experimental triple-agonist showing even more dramatic results in preclinical models. Obesity-Related Cancers: Why fatty liver, chronic inflammation, and nutrient-sensing pathways (like mTOR) create a "pro-cancer milieu." The "Foundational Four": Why, despite all the medical breakthroughs, sleep, clean eating, stress management, and exercise remain the ultimate levers for health. Dr. Holthouse also shares his "minimalist" approach to detoxification and why he's more interested in "reining patients in" from expensive gadgets to focus on what actually moves the needle. Whether you are interested in the latest longevity science or simply looking for ways to lower your family's risk of chronic disease, this conversation is packed with "root cause" insights you won't want to miss.

Could GLP-1 medications be the missing piece in treating inflammatory skin disease? In this episode of Science is Skin, Dr. Ted Lain sits down with Dr. Lindsey Bordone — former Columbia University associate professor of dermatology, now in private practice at Bordone Dermatology in Scottsdale, Arizona — for a deep dive into metabolic disease and the skin. Dr. Bordone was among the first dermatologists to prescribe GLP-1 agonists for her patients, and in this conversation she explains exactly why. From the link between hyperinsulinemia and chronic inflammation to the visible skin signs of insulin resistance — skin tags, acanthosis nigricans, forearm hair loss — she makes the case that dermatologists are uniquely positioned to catch metabolic disease before any other specialty. Dr. Bordone walks through how she uses tirzepatide (Mounjaro/Zepbound), semaglutide (Ozempic/Wegovy), and the emerging triple-G drug retatrutide, including her lab protocols, dosing philosophy, how to manage GI side effects, and the surprising interaction between GLP-1s and estrogen therapy. In this episode: Why high BMI reduces biologic efficacy in psoriasis patients How to check fasting insulin (HOMA-IR) and why most physicians aren't doing it Skin signs of insulin resistance: skin tags, forearm hair loss, and neck skin thickening Tirzepatide vs. semaglutide vs. retatrutide — how to choose and when Retatrutide's remarkable 93% fatty liver clearance rate in clinical trials The truth about sarcopenia and muscle loss on GLP-1 medications Dosing protocols, side effect management, and when NOT to escalate quickly Protein intake recommendations during active weight loss Estrogen and GLP-1 synergy — what dermatologists need to know Lab work to run before and during GLP-1 therapy How to build an insurance case for continued medication coverage Resources mentioned: HOMA-IR fasting insulin/glucose testing AAD resources on metabolic dermatology Bordone Dermatology — Scottsdale, Arizona Enjoyed this episode? Share it with a colleague and leave us a five-star review. Subscribe so you never miss an episode of Science is Skin. To watch this and other episodes, be sure to check out our YouTube page DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.See omnystudio.com/listener for privacy information.

We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: -Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health -Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine. Selected references: -Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 -Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 -Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 -Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

It's In The News - where we bring you the top diabetes stories and headlines happening now. This week, Tzield approved down to age one and over, Omnipod trials for fully closed loop, Tandem approved for pregnancy, Eversense 365 launches in Europe, generic Ozempic in Canada, an award for the T1D Barbie and more.  Announcing Community Commericals! Learn how to get your message on the show here. Don't miss our in-person events: www.diabetes-connections.com/events  Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Okay.. our top story this week: XX The U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) for use in children in stage 2 type 1 diabetes (T1D) ages one and older. The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from the PETITE-T1D Phase IV study, which evaluated the safety and pharmacokinetics of Tzield in children under eight years old. Tzield was approved for use in individuals 8+ in stage 2 T1D in 2022. Since then, we have been working to expand the eligible population. This expansion effort includes individuals in stage 3 T1D, who can preserve endogenous insulin production for longer when they take Tzield and, most notably today, children in stage 2. https://www.breakthrought1d.org/news-and-updates/tzield-approved-for-children-ages-one-and-older-in-stage-2-t1d/   XX Big write up in the journal Pediatrics about screening for type 1. Citing the 2025 ADA Standards of Care in Diabetes, the opinion piece talks about how to engage the greater healthcare community.  It says: We aim to encourage the development of strategies to emphasize the importance of T1D early detection, integrate screening into routine health care encounters, and support implementation of T1D screening. Pediatricians and other primary care clinicians are well positioned for greater collaboration with the multidisciplinary team, ensuring early detection, timely intervention, and improved outcomes. https://publications.aap.org/pediatricsopenscience/article/2/2/1/207272/Type-1-Diabetes-Screening-in-Pediatrics-Putting?autologincheck=redirected   XX More info about GLP-1 drugs and people with type 1. New study shows off label use did not lead to DKA or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist use in people with T1D was associated with lower overall rates of hospitalization, as has occurred in type 2 diabetes Although GLP-1 agonists are not approved by the FDA for T1D management, off-label adjunctive use has risen for those with obesity. Semaglutide was the most commonly-used GLP-1 (65.5% of GLP-1 users) followed by tirzepatide (23.5%). The rest were using the older-generation drugs: liraglutide or dulaglutide. Lots more information to come on type 1 and glp 1-s in upcoming studies. https://www.medscape.com/viewarticle/use-glp-1s-type-1-diabetes-not-linked-increased-dka-2026a1000d56 XX Health Canada ‌​has approved the first generic ​version of ​Danish ⁠drugmaker ⁠Novo ‌Nordisk's Ozempic drug. In January 2026, the Canadian patent for Ozempic will expire, paving the way for cheap generic versions of the semaglutide injections that help regulate blood sugar levels and appetite. Health Canada said this generic, like existing products, is indicated to be used for the "once-weekly treatment of adult patients with Type 2 diabetes to manage blood sugar levels." With three generics on the market, Tadrous said the price could drop to about $100 or less, depending on their dose. Health Canada said it's currently reviewing eight other generic submissions by different companies and expects to make a decision on these in the next few weeks and months. https://www.cbc.ca/news/health/ozempic-generic-health-canada-9.7180566 XX  Insulet has enrolled the first participant in a pivotal study for its fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes (T2D  The participants are between 18 – 75 years of age, living with T2D and using insulin (basal-bolus or basal-only). The Company received Investigational Device Exemption (IDE) approval in March 2026 from the U.S. Food and Drug Administration (FDA). The Company plans to submit a 510(k) filing to the FDA in 2027 and launch its FCL AID system for T2D in 2028.   XX insulet Corporation (PODD) has initiated a voluntary recall of certain lots of its Omnipod 5 insulin delivery Pods in the U.S. after detecting that some devices had a manufacturing defect that causes insulin leakage.   Patients using the affected devices could risk experiencing high blood glucose levels due to insufficient insulin delivery, the Acton, Massachusetts-based MedTech disclosed in a statement late Thursday. The company has already notified the FDA about the recall, which it said will affect nearly 1.5% of Omnipod 5 pod units it manufactures annually. The customers were advised to immediately seek a product replacement at no cost if a Pod from a defective lot is currently in use. https://www.msn.com/en-us/money/companies/insulet-recalling-certain-defective-omnipod-insulin-delivery-devices/ar-AA1YyslT?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c XX Tandem Diabetes Care (Nasdaq:TNDM) gets FDA clearance for its automated insulin delivery (AID) technology for use in pregnancy. The FDA cleared the company's Control-IQ AID technology for use in what they call: pregnancy complicated by type 1 diabetes mellitus. Tandem says t:slim X2 and Mobi are the first and only commercially available AID systems cleared for use during pregnancy in the U.S. https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/ XX Tandem also issued an urgent medical device correction for a software problem with its Mobi insulin pumps. The malfunction may cause insulin delivery to stop, causing high blood sugar if not addressed, the Food and Drug Administration said in a Wednesday recall notice. We told you about this back in October when Tandem sent a letter to customers notifying them of the fault and instructing them to update their pump software as soon as possible. The FDA now issued a class one recall, the most serious type. We just released a bonus episode all about Tanem – tubeless mobi and what else is in the pipeline. You can listen to that wherever you are listening to this.. it's the episode just before this one. https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pumps-over-software-malfunction/818260/   XX Switching CGMs didn't make a measurable difference for adults using MiniMed's pump system. In a real-world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes, researchers found that CGM metrics for patients who switched from the Guardian 4 sensor (MiniMed) to Instinct by Abbott were able to maintain a time in range of greater than 75%. "When it comes to the automated insulin delivery system ... I think the sensor matters less and the system matters more," Viral N. Shah, MD, professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases, said during a presentation. "Having a different sensor with the system, I think the [glycemic] outcomes will still be what you want." I'm including this because the headline here seemed to indicate no CGM makes a difference, but this study only looked at two. https://www.healio.com/news/endocrinology/20260401/switching-cgm-sensors-does-not-impact-glycemic-outcomes-with-automated-insulin-delivery   XX Vitamin D supplementation may help delay or prevent disease progression in people with prediabetes.. in people who have specific variants in their vitamin D receptor gene. This was found after a second look at large study where researchers found vitamin d really did make a difference.. a second look with people who had a specific gene variation had much better results. "More research is needed to see if there are other factors that are associated with risk reduction." https://www.medicalnewstoday.com/articles/vitamin-d-supplements-help-prevent-type-2-diabetes-right-gene-variants   XX Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. Eversense 365 is the world's first 365-day CGM system. It also holds clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems, like the Sequel Med Tech twiist system. The company said it made Eversense 365 available to the first patients in Sweden. It plans to bring the sensor to Germany, Spain and Italy in the coming weeks https://www.drugdeliverybusiness.com/senseonics-launches-eversense-365-europe/ XX A machine learning model can improve genetic prediction of type 1 diabetes by as much as 10%, show results from a University of California, San Diego study.   The researchers used the machine‑learning model T1GRS to improve on a gold standard polygenic genetic risk score used to predict who is likely to develop the condition called GRS2. The GRS2 polygenic risk score has been widely tested and can be used to predict newborns who are at high risk of developing type 1 diabetes. While early prediction can't necessarily stop the disease it can help to prevent emergencies like diabetic ketoacidosis at diagnosis, allow families time to prepare and could allow use of therapies to delay onset of the condition. In this study, Gaulton and colleagues carried out a genome‑wide association study in 20,355 people with type 1 diabetes and 797,363 non‑diabetic Europeans, as well as a further analysis around the MHC region in 10,107 diabetic and 19,639 nondiabetic individuals. https://www.insideprecisionmedicine.com/topics/molecular-dx/machine-learning-tool-helps-improve-type-1-diabetes-prediction/ XX Sen. Mark Warner (D-Va.) said Monday that he will return to the upper chamber this week after taking time off for the death of his daughter, Madison.   The Virginia senator wrote on the social platform X, "As we remember our incredible daughter, Maddy, my family has been deeply touched by the outpouring of support we've received. Thank you to everyone for your kind words." Madison Warner, 36, died earlier this month after a decades-long battle with juvenile diabetes and other health issues. Mark Warner and his wife, Lisa Collis, wrote in a statement last Monday that they were "heartbroken beyond words" by their daughter's passing.   On Monday, the former Virginia governor said his daughter "was a deeply empathetic and engaged person" and that "as recently as the day she passed, she was full of ideas and suggestions" for him, including how he could improve his social media presence.   "She used to say to me: 'Dad, you have the power — you have to use it.' She pushed me to make the most of my position, to use my seat in the Senate to help people in meaningful ways," he added.       "If I can find any solace during this time, it's that I have the enormous privilege to serve Virginians and the responsibility to keep working for a better, more just world in Maddy's name."   Warner concluded, "I look forward to returning to the Senate this week and continuing that essential work."   Madison Warner is survived by two younger sisters.     An estimated than 2.1 million Americans, including about 314,000 children and adolescents younger than age 20, have diagnosed type 1 diabetes as of March — which is what juvenile diabetes is commonly called — according to the CDC's National Diabetes Statistics Report.   An estimated 11 million U.S. adults have undiagnosed diabetes, the report notes.   Symptoms of type 1 diabetes include feeling more thirsty than usual, urinating a lot, bed-wetting in children who have never done so, feeling very hungry and losing weight without trying, according to the Mayo Clinic. https://thehill.com/homenews/senate/5851605-mark-warner-diabetes-death/ XX Mattel, Inc. and Breakthrough T1D just won a Gold Halo Award for Best Cause Product Initiative for the launch of the first Barbie with T1D.  The Halo Awards recognize the most outstanding corporate social impact efforts over the past year.

In this episode of The Better Life, Dr. Mary Ann Pinkston sits down with Ray Solano of PD Labs to explore the cutting edge of peptide therapy: transdermal delivery. Moving away from traditional injections, they discuss the science of getting potent peptides like BPC-157, MOTC, and CJC/Ipamorelin into the body through the skin. Solano explains the importance of pharmaceutical quality over "black market" alternatives and reveals a potential breakthrough in topical Semaglutide for metabolic health. From upregulating mitochondria to improving sleep and reducing inflammation, discover how these "magic lotions" are making integrative medicine more accessible and effective. Key Takeaways The Shift to Transdermal: Advancements in specialized bases now allow fragile peptides to bypass the digestive system and needles, absorbing directly into the bloodstream. Mitochondrial & Energy Support: Insights into MOTC for cellular energy and CJC/Ipamorelin for natural growth hormone signaling. Innovation in Weight Management: A discussion on the potential for topical Semaglutide to address "food noise" and metabolic changes without injections. Quality Matters: Why sourcing from a compounding pharmacy is critical to avoid the "moonshine" version of synthetic peptides found online. See omnystudio.com/listener for privacy information.

Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month, they discuss: Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277 Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283 Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767 Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238 Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063 Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

GLP-1 drugs like Ozempic and Mounjaro are now everywhere. But what do they actually do beyond weight loss? And what do you need to know before starting them? In this episode, we're joined by Dr Ania Jastreboff, a world-leading researcher at the forefront of GLP-1 treatments and writer of the New York Times bestselling book Enough: Your Health, Your Weight, and What It's Like To Be Free, co-authored with Oprah Winfrey. Dr Jastreboff explains everything you need to know about Ozempic, Mounjaro, Wegovy and other GLP-1 medications for 2026. You'll learn how GLP-1s may reduce the risk of heart disease, improve blood sugar control, and support conditions like sleep apnoea. We also explore why weight often returns after stopping, and what you need to know about Ozempic side effects and long-term use. If these drugs can change how your brain controls hunger, what does that mean for willpower, weight gain, and how we treat obesity long term?

Three years ago, GLP-1 peptides were barely being talked about in the midlife women's health space. Since then, Jessica and I have personally used them, experimented with different approaches, and helped over a thousand women inside our peptide program navigate what works, what backfires, and what women in perimenopause and menopause need to know before jumping in. In this episode, we're pulling back the curtain on our own GLP-1 journeys, including my rough start with Ozempic, why Tirzepatide worked better for me, Jessica's experience with Semaglutide and fatigue, and why Retatrutide is becoming one of the most talked-about peptides right now. We also get into one of the biggest myths floating around online: that GLP-1s automatically cause massive muscle loss. The truth is much more nuanced. We talk about the biggest mistakes we see women making. How Glp1s can impact insulin sensitivity, inflammation, fat cell biology, blood sugar regulation, liver metabolism, and even brain reward pathways. We also dive into some of the peptides we're loving right now beyond GLP-1s, including NAD, KPV, MOTS-c, and Tesamorelin, and why peptide therapy can be powerful when it's used intelligently, not recklessly. This is a real, honest conversation about how to use these tools in a way that supports long-term health, metabolism, muscle, and hormones, instead of chasing fast weight loss at any cost. In this episode, we cover: Our personal three-year journey using GLP-1 peptides Why Ozempic, Semaglutide, Tirzepatide, and Retatrutide can feel very different The truth about GLP-1s and muscle loss Why appetite suppression is not the only sign a GLP-1 is working The biggest mistakes women make with dosing and titration Why protein, amino acids, digestion, and strength training matter so much How GLP-1s may support insulin sensitivity, inflammation, blood sugar, and metabolic health Why some women don't lose weight until thyroid, hormones, food sensitivities, or inflammation are addressed What we're seeing with Retatrutide and why it's getting so much attention Peptides beyond GLP-1s, including NAD, KPV, MOTS-c, and Tesamorelin Who This Episode Is For This episode is for women in perimenopause or menopause who are using GLP-1s, thinking about starting them, or wondering why they are not getting the results they expected. It is especially helpful if you are worried about muscle loss, hair shedding, fatigue, dosing, long-term use, maintenance, or whether peptides are actually supporting your metabolism or just helping you eat less.     Sponsors Join our FREE upcoming masterclass: Why Midlife Weight Gain Won't Budge A smarter way to use GLP-1s in midlife without wrecking muscle or metabolism When: April 30th 11 am PST Register here: https://coaching.karenmartel.com/glp1-masterclass    Add MitoQ Hormonal Metabolic Support to your midlife support toolbox: www.mitoq.com/karenmartel get 10% off your order with code: MARTEL10     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

Most disciplined executives and entrepreneurs aren't struggling with fat loss because of effort or willpower. They're struggling because they're out of sequence—jumping straight to peptides, compounds, and advanced protocols before the three biological levers that actually drive fat loss are even stable.In this episode, Julian Hayes II breaks down the exact three mechanisms that determine whether your body gets lean and stays lean—and how to pull each one in the right direction before layering in anything advanced.You'll walk away understanding why fat loss is a sequencing problem, not a knowledge problem, and what it actually looks like to build a metabolic foundation that performs the way your business does. For executives and entrepreneurs operating in high-stakes environments, this episode connects biology directly to business performance.— Episode Chapter Big Ideas (timing may not be exact) —0:00 – Why disciplined high performers still don't look the part 1:57 – The three biological levers behind sustainable fat loss2:51 – About Julian and Executive Health3:26 – Who this conversation is actually for 4:49 – Lever 1: Nutrient Partitioning: where do your calories actually go?6:04 – The capital allocation analogy: investing in lean tissue vs. storing fat6:50 – The four factors that determine partitioning efficiency12:26 – Practical foundation: how to optimize partitioning before going advanced13:19 – Earning your carbs: the Charles Poliquin philosophy15:30 – GLP-1 receptor agonists and nutrient partitioning15:49 – Testosterone and hormonal optimization: Why hormones make everything go18:06 – Lever 2: Recovery Signaling: Where most high performers self-sabotage19:09 – What recovery signaling actually controls in a deficit19:33 – Cortisol21:02 – Growth hormone22:07 – Thyroid conversion: the T4 to T3 problem nobody talks about24:15 – HRV: your autonomic nervous system's engine light27:07 – Practical recovery: sleep timing and maximizing slow-wave GH pulses28:53 – Protein in a deficit: the primary defense against muscle loss29:39 – Electrolytes, magnesium, and why micronutrients matter more on GLPs32:51 – Advanced layer: CJC-1295 and Ipamorelin34:17 – Exogenous HGH: beyond bodybuilding34:54 – BPC-157 and TB-500: the gateway peptides for recovery35:58 – The 90/95 rule: foundation is the work, advanced tools are the amplifier36:34 – Lever 3: Appetite and Energy Regulation: the compliance lever37:22 – Why fat loss is a compliance problem, not a knowledge problem37:34 – Food noise is biological, not psychological38:51 – What poor appetite regulation actually costs executives40:24 – How aggressive deficits suppress testosterone41:15 – Performance as the feedback loop for energy regulation43:00 – Fiber, gut health, and natural GLP-1 secretion44:06 – Meal timing and circadian biology46:52 – Advanced layer: Semaglutide, Tirzepatide, and Retatrutide explained50:30 – Muscle loss, GI risk, and why lifestyle habits are the real variable51:24 – Genetics and fat loss52:47 – Low-dose Naltrexone54:19 – Thymosin Alpha-1 and emerging peptide research on energy regulation55:36 – Tying it all together: Foundation First, Amplification Second57:01 – The cost of skipping a sequence59:05 – The executive case for fat loss beyond aesthetics1:01:30 – How to work with Julian privately— Connect with Julian and Executive Health —LinkedIn — https://www.linkedin.com/in/julianhayesii/X — https://x.com/thejulianhayesReady to take your health, leadership, and performance to the next level? Book an exploratory call —https://www.executivehealth.io/contactWebsite — https://www.executivehealth.io/***DISCLAIMER: The information shared is not meant to treat or diagnose any condition. This is for educational, informational, and entertainment purposes. The content here is not intended to replace your relationship with your doctor and/or medical practitioner. Consult your provider before making any decisions.

Is oatmeal healthy?I have a higher-than-normal carotid artery intima-media thickness and no appreciable plaque. Should I be concerned?Should my husband and I take the hepatitis B vaccine?

 Ozempic. Semaglutide. GLP-1s. Everyone's talking about them — but nobody's telling you the whole truth. Dr. Tabatha sits down with functional medicine physician Dr. Rika to break down what peptides actually are, who should be on GLP-1s, and what happens when you stop. What a peptide actually is — in plain EnglishHow your body makes over 7,000 peptides and what happens as they declineGLP-1s explained: how they work, who they're for, who they're not forThe shocking muscle loss stats nobody tells you before you startWhy gut health determines how well GLP-1s work — and your side effectsThe difference between semaglutide, tirzepatide, and what's coming nextHow to come off GLP-1s without reboundingMicrodosing for inflammation, brain health, and heart protectionWhy postmenopausal women lose less weight on GLP-1s without hormonesToxins stored in fat cells — and why they block weight lossMetabo Lift: the natural herbal supplement that boosts your body's own GLP-1 by 55%Resources: Dr. Rajka's Book: https://amzn.to/4t6ZWjp Free Longevity Quiz → thelongevityscore.com Metabo Lift → shop.fasttofaith.com/product/metabo-lift/ Use code PODCAST for 20% offTIMESTAMPS00:00 — "Aging is inevitable. Decline doesn't have to be." 00:13 — Welcome to Fast to Faith 01:26 — Introducing Dr. Rika: the go-to doctor for doctors 02:51 — Why doctors come to Dr. Rika for help 04:36 — What is a peptide? The biologic text message explained 07:23 — Does your body make peptides naturally? 08:15 — What is a GLP-1 and how does it work? 09:12 — The danger of buying GLP-1s online 09:31 — Who should be on a GLP-1 — and who shouldn't 11:10 — GLP-1s as band-aid medicine — what happens when you stop 12:21 — Muscle loss: the shocking stat nobody tells you 12:51 — Semaglutide vs. tirzepatide vs. what's coming next 13:44 — GI side effects and the gut foundation that prevents them 16:33 — The real cost of going on GLP-1s without laying the foundation 18:11 — Metabo Lift: naturally boosting your own GLP-1 by 55% 20:27 — Muscle loss, bone loss, and what you must do while on GLP-1s 22:58 — Why root causes are never addressed in online clinics 23:23 — What does coming off GLP-1s actually look like? 24:58 — Microdosing GLP-1s: benefits for inflammation, brain, and heart 27:35 — How long should you stay on them? 28:48 — Fat cells store toxins — and that's why you can't lose weight 31:52 — Genetics, detox pathways, and who needs deeper testing 33:31 — Dr. Rika's glutathione moment that changed everything 35:56 — Growth hormone peptides and what's coming for longevity 38:34 — Oral vs. injectable peptides — what we know 38:60 — How to find and work with Dr. Rika 40:48 — Closing: Proverbs 3:7-8Ready to stop trying harder and start healing smarter? Start with the $5 Faith Reset Challenge — your first step to regulating your nervous system, stabilizing your metabolism, and reconnecting with your identity in Christ through simple, faith-centered rhythms. This is where most women begin. 

In this episode, we discuss the most important annual updates in the American Diabetes Association Guidelines, Standards of Care 2026, particularly focusing on changes in pharmacotherapy recommendations and the supporting evidence. Key Concepts A few existing agents now have ASCVD risk reduction data in patients with existing ASCVD or high indicators for ASCVD. They are: oral semaglutide and tirzepatide.  SGLT2is are still first-line in patients with diabetes and HF including HFpEF, but SC semaglutide and tirzepatide are now recommended for those with symptomatic HFpEF and obesity due to positive outcomes in this population. The GLP-1RA and dual GLP-1/GIP RA are the preferred agents for weight management in patients with T2DM, but use of GLP-1RA can be considered for weight loss in patients with T1DM. The guideline also better defines recommendations for medication-induced hyperglycemia from immune checkpoint inhibitors, PI3Kɑ (phosphoinositidylinositol 3-kinase α) inhibitors, mTOR inhibitors, and steroids.  References American Diabetes Association. Standards of care in diabetes—2026. Diabetes Care. 2026;49(suppl 1):S1-S377. SOUL study. Darren K. McGuire, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001-2012. doi:10.1056/NEJMoa2501006. SURPASS-CVOT. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928. SUMMIT. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027. STEP-HFpEF. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963. STEP-HFpEF DM. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity‑related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394‑1407. doi:10.1056/NEJMoa2313917.